Lynparza granted Priority Review in the US for BRCA-mutated HER2-negative high-risk early breast…
AstraZeneca’s supplemental New Drug Application (sNDA) for Lynparza (olaparib) has been accepted and granted Priority Review in the US for the adjuvant treatment of patients with…
Read More...
Read More...
